Human antibody specificities that confer protective immunity to poxvirus infections (VAC11P.1109)

Iuliia M. Gilchuk(Vanderbilt University Medical Center), James E. Crowe(Vanderbilt University Medical Center), Roselyn J. Eisenberg(Unknown), Pavlo Gilchuk(AstraZeneca (Japan)), Sebastian Joyce(Walther Cancer Foundation), Mark K. Slifka(Oregon Health & Science University), Erika Hammarlund(Oregon National Primate Research Center), Gopal Sapparapu(Vanderbilt University Medical Center), Rebecca Lampley(National Institutes of Health), Yan Xiang(Sichuan University), Gary H. Cohen(University of Pennsylvania)
The Journal of Immunology
May 1, 2015
10.4049/jimmunol.194.supp.212.17
Cited by 1

Related Papers

Potently neutralizing and protective human antibodies against SARS-CoV-2
|Nature|2020|1.2k
Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition
|Cell Host & Microbe|2020|1.2k
Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies
|Nature Medicine|2021|1k
Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants
|Science|2021|602
Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein
|Nature Medicine|2020|543